tenofovir disoproxil fumarate + emtricitabine pod-IVR

This drug is a combination of tenofovir disoproxil fumarate (TDF) and emtricitabine (FTC) formulated for delivery via a pod-intravaginal ring (pod-IVR). Developed by the Oak Crest Institute of Science, the pod-IVR is an innovative drug delivery system consisting of a silicone scaffold that holds up to 10 individual pods of polymer-coated drug cores. This design allows for the independently controlled release of each active ingredient through delivery channels. TDF and FTC are both nucleoside reverse transcriptase inhibitors (NRTIs) that work by inhibiting the HIV reverse transcriptase enzyme, thereby preventing the replication of the virus in vaginal tissues. The formulation is specifically designed for HIV pre-exposure prophylaxis (PrEP) in women and has been evaluated in Phase I clinical trials for safety and pharmacokinetics.

Brand names

Teno-em

Other names

TDF-FTC IVRpod-intravaginal ring